Which has higher valuation and earnings, GLAS or TARA?

Glass House Brands has higher revenue and earnings than Protara Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands $176.02M 5.22 N/A N/A N/A Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A

Is GLAS or TARA more profitable?

Glass House Brands' return on equity of 0.00% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Glass House Brands N/A N/A N/A Protara Therapeutics N/A -38.70% -36.02%

Does the media favor GLAS or TARA?

In the previous week, Protara Therapeutics had 1 more articles in the media than Glass House Brands. MarketBeat recorded 4 mentions for Protara Therapeutics and 3 mentions for Glass House Brands. Protara Therapeutics' average media sentiment score of 1.23 beat Glass House Brands' score of -0.18 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, TARA or ANNX?

Annexon is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is TARA or ANNX more profitable?

Protara Therapeutics' return on equity of -38.70% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% Annexon N/A -101.19% -75.99%

Does the media favor TARA or ANNX?

In the previous week, Protara Therapeutics and Protara Therapeutics both had 4 articles in the media. Protara Therapeutics' average media sentiment score of 1.23 beat Annexon's score of 0.52 indicating that Protara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TARA or PHAT?

In the previous week, Protara Therapeutics had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 4 mentions for Protara Therapeutics and 2 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.89 beat Protara Therapeutics' score of 1.23 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to TBPH or TARA?

In the previous week, Theravance Biopharma had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 5 mentions for Theravance Biopharma and 4 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.23 beat Theravance Biopharma's score of 0.31 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ANRO or TARA?

Alto Neuroscience is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A

Is ANRO or TARA more profitable?

Protara Therapeutics' return on equity of -38.70% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Protara Therapeutics N/A -38.70% -36.02%

Does the media refer more to ANRO or TARA?

In the previous week, Alto Neuroscience and Alto Neuroscience both had 4 articles in the media. Protara Therapeutics' average media sentiment score of 1.23 beat Alto Neuroscience's score of 0.73 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Protara Therapeutics (TARA) Competitors

$4.18 -0.14 (-3.24%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$4.30 +0.12 (+2.75%)

As of 05:05 AM Eastern

Compare

TARA vs. GLAS, ANNX, PHAT, TBPH, and ANRO

Should you buy Protara Therapeutics stock or one of its competitors? MarketBeat compares Protara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protara Therapeutics include Glass House Brands (GLAS), Annexon (ANNX), Phathom Pharmaceuticals (PHAT), Theravance Biopharma (TBPH), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry.

How does Protara Therapeutics compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Protara Therapeutics (NASDAQ:TARA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

38.1% of Protara Therapeutics shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Glass House Brands presently has a consensus price target of $17.00, suggesting a potential upside of 48.46%. Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 527.99%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Glass House Brands has higher revenue and earnings than Protara Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$176.02M	5.22	N/A	N/A	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

In the previous week, Protara Therapeutics had 1 more articles in the media than Glass House Brands. MarketBeat recorded 4 mentions for Protara Therapeutics and 3 mentions for Glass House Brands. Protara Therapeutics' average media sentiment score of 1.23 beat Glass House Brands' score of -0.18 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Protara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glass House Brands' return on equity of 0.00% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Protara Therapeutics	N/A	-38.70%	-36.02%

Summary

Protara Therapeutics beats Glass House Brands on 7 of the 11 factors compared between the two stocks.

How does Protara Therapeutics compare to Annexon?

Protara Therapeutics (NASDAQ:TARA) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Protara Therapeutics' return on equity of -38.70% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Annexon	N/A	-101.19%	-75.99%

Protara Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Annexon has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

38.1% of Protara Therapeutics shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by insiders. Comparatively, 10.3% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Protara Therapeutics and Protara Therapeutics both had 4 articles in the media. Protara Therapeutics' average media sentiment score of 1.23 beat Annexon's score of 0.52 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics presently has a consensus price target of $26.25, indicating a potential upside of 527.99%. Annexon has a consensus price target of $16.00, indicating a potential upside of 184.19%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Protara Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Annexon is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Summary

Protara Therapeutics beats Annexon on 10 of the 12 factors compared between the two stocks.

How does Protara Therapeutics compare to Phathom Pharmaceuticals?

Protara Therapeutics (NASDAQ:TARA) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Protara Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Protara Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Protara Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Phathom Pharmaceuticals	$175.11M	4.97	-$221.25M	-$2.12	N/A

Protara Therapeutics currently has a consensus target price of $26.25, suggesting a potential upside of 527.99%. Phathom Pharmaceuticals has a consensus target price of $24.50, suggesting a potential upside of 124.56%. Given Protara Therapeutics' higher probable upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Protara Therapeutics had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 4 mentions for Protara Therapeutics and 2 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.89 beat Protara Therapeutics' score of 1.23 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phathom Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Protara Therapeutics beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Protara Therapeutics compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

In the previous week, Theravance Biopharma had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 5 mentions for Theravance Biopharma and 4 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.23 beat Theravance Biopharma's score of 0.31 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Theravance Biopharma has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.11	$105.89M	$2.20	7.68
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

Theravance Biopharma presently has a consensus target price of $19.40, indicating a potential upside of 14.79%. Protara Therapeutics has a consensus target price of $26.25, indicating a potential upside of 527.99%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Theravance Biopharma has a net margin of 104.34% compared to Protara Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Protara Therapeutics	N/A	-38.70%	-36.02%

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Theravance Biopharma has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Summary

Theravance Biopharma beats Protara Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Alto Neuroscience and Alto Neuroscience both had 4 articles in the media. Protara Therapeutics' average media sentiment score of 1.23 beat Alto Neuroscience's score of 0.73 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alto Neuroscience is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

Alto Neuroscience has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Protara Therapeutics' return on equity of -38.70% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Protara Therapeutics	N/A	-38.70%	-36.02%

Alto Neuroscience currently has a consensus price target of $35.25, suggesting a potential upside of 25.46%. Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 527.99%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

38.1% of Protara Therapeutics shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Protara Therapeutics beats Alto Neuroscience on 10 of the 12 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARA vs. The Competition

Export

Metric	Protara Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$242.80M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-3.12	19.17	27.11	24.26
Price / Sales	N/A	838.79	589.14	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	1.10	4.22	10.75	6.29
Net Income	-$57.44M	$64.26M	$3.58B	$330.66M
7 Day Performance	-2.11%	-3.58%	-2.10%	-1.35%
1 Month Performance	7.18%	2.12%	3.29%	-0.64%
1 Year Performance	32.28%	20.35%	26.32%	19.08%

Protara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARA Protara Therapeutics	3.1223 of 5 stars	$4.18 -3.2%	$26.25 +528.0%	+37.0%	$242.80M	N/A	N/A	30	Positive News
GLAS Glass House Brands	N/A	$11.32 -9.4%	N/A	N/A	$908.68M	$176.02M	N/A	N/A	Positive News Analyst Upgrade Gap Up
ANNX Annexon	3.3566 of 5 stars	$5.96 +9.2%	$16.00 +168.5%	+118.2%	$894.58M	N/A	N/A	60	Positive News Analyst Downgrade
PHAT Phathom Pharmaceuticals	2.2277 of 5 stars	$11.38 +1.6%	$24.50 +115.3%	+18.8%	$893.27M	$175.11M	N/A	110	News Coverage
TBPH Theravance Biopharma	3.0214 of 5 stars	$17.00 +0.4%	$21.40 +25.9%	+49.6%	$872.79M	$107.46M	7.73	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protara Therapeutics (TARA) Competitors

TARA vs. GLAS, ANNX, PHAT, TBPH, and ANRO

How does Protara Therapeutics compare to Glass House Brands?

Summary

How does Protara Therapeutics compare to Annexon?

Summary

How does Protara Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Protara Therapeutics compare to Theravance Biopharma?

Summary

How does Protara Therapeutics compare to Alto Neuroscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protara Therapeutics (TARA) Competitors

TARA vs. GLAS, ANNX, PHAT, TBPH, and ANRO

How does Protara Therapeutics compare to Glass House Brands?

Do institutionals & insiders hold more shares of GLAS or TARA?

Do analysts recommend GLAS or TARA?

Which has higher valuation and earnings, GLAS or TARA?

Does the media favor GLAS or TARA?

Is GLAS or TARA more profitable?

Summary

How does Protara Therapeutics compare to Annexon?

Is TARA or ANNX more profitable?

Which has more volatility and risk, TARA or ANNX?

Do institutionals & insiders believe in TARA or ANNX?

Does the media favor TARA or ANNX?

Do analysts recommend TARA or ANNX?

Which has better valuation and earnings, TARA or ANNX?

Summary

How does Protara Therapeutics compare to Phathom Pharmaceuticals?

Which has more risk and volatility, TARA or PHAT?

Is TARA or PHAT more profitable?

Which has better valuation & earnings, TARA or PHAT?

Do analysts prefer TARA or PHAT?

Do insiders and institutionals have more ownership in TARA or PHAT?

Does the media favor TARA or PHAT?

Summary

How does Protara Therapeutics compare to Theravance Biopharma?

Does the media refer more to TBPH or TARA?

Which has preferable earnings and valuation, TBPH or TARA?

Do analysts rate TBPH or TARA?

Is TBPH or TARA more profitable?

Do institutionals & insiders believe in TBPH or TARA?

Which has more volatility & risk, TBPH or TARA?

Summary

How does Protara Therapeutics compare to Alto Neuroscience?

Does the media refer more to ANRO or TARA?

Which has preferable earnings & valuation, ANRO or TARA?

Which has more volatility and risk, ANRO or TARA?

Is ANRO or TARA more profitable?

Do analysts prefer ANRO or TARA?

Do institutionals & insiders believe in ANRO or TARA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools